JNK1, a potential therapeutic target for hepatocellular carcinoma

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1796, Issue 2, 2009, Pages 242-251

  Chen, Fei ^a   Beezhold, Kevin ^a   Castranova, Vince ^a  

^a Pathology and Physiology Research Branch   (United States)

Author keywords

Epigenetics; HCC; JNK1; Progenitor cells; ROS; Signature genes

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; ISOENZYME; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; LAPATINIB; REACTIVE OXYGEN METABOLITE; SORAFENIB; SUNITINIB;

CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; ENZYME ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE GENETICS; REVIEW; STEM CELL; SURVIVAL RATE; SURVIVAL TIME; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, HEPATOCELLULAR; ENZYME ACTIVATION; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MOLECULAR SEQUENCE DATA; REACTIVE OXYGEN SPECIES; UBIQUITIN;

EID: 70349183424     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.06.005     Document Type: Review

References (130)

1. Kyriakis J.M., and Avruch J. pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-l-lysine. J. Biol. Chem. 265 (1990) 17355-17363
2. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1994) 1025-1037
3. Smeal T., Binetruy B., Mercola D.A., Birrer M., and Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354 (1991) 494-496
4. Kennedy N.J., and Davis R.J. Role of JNK in tumor development. Cell Cycle 2 (2003) 199-201
5. Licato L.L., and Brenner D.A. Analysis of signaling protein kinases in human colon or colorectal carcinomas. Dig. Dis. Sci. 43 (1998) 1454-1464
6. Hirano T., Shino Y., Saito T., Komoda F., Okutomi Y., Takeda A., et al. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 21 (2002) 5923-5928
7. Wang H.Y., Cheng Z., and Malbon C.C. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191 (2003) 229-237
8. Papachristou D.J., Batistatou A., Sykiotis G.P., Varakis I., and Papavassiliou A.G. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone 32 (2003) 364-371
9. Czibere A., Prall W.C., Zerbini L.F., Jager M., Kobbe G., Knipp S., et al. Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS. Br. J. Haematol. 135 (2006) 355-357
10. Khatlani T.S., Wislez M., Sun M., Srinivas H., Iwanaga K., Ma L., et al. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26 (2007) 2658-2666
11. Lotan T.L., Lyon M., Huo D., Taxy J.B., Brendler C., Foster B.A., et al. Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J. Pathol. 212 (2007) 386-394
12. Gross N.D., Boyle J.O., Du B., Kekatpure V.D., Lantowski A., Thaler H.T., et al. Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. Clin. Cancer Res. 13 (2007) 5910-5917
13. Mangiola A., Lama G., Giannitelli C., De Bonis P., Anile C., Lauriola L., et al. Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin. Cancer Res. 13 (2007) 6970-6977
14. Li J.Y., Wang H., May S., Song X., Fueyo J., Fuller G.N., et al. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J. Neurooncol. 88 (2008) 11-17
15. Shibata W., Maeda S., Hikiba Y., Yanai A., Sakamoto K., Nakagawa H., et al. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 68 (2008) 5031-5039
16. Chang Q., Zhang Y., Beezhold K.J., Bhatia D., Zhao H., Chen J., et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J. Hepatol. 50 (2009) 323-333
17. Hui L., Zatloukal K., Scheuch H., Stepniak E., and Wagner E.F. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118 (2008) 3943-3953
18. Chen F., and Castranova V. Beyond apoptosis of JNK1 in liver cancer. Cell Cycle 8 (2009) 1145-1147
19. Weston C.R., and Davis R.J. The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19 (2007) 142-149
20. Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15 (1996) 2760-2770
21. Liu J., Minemoto Y., and Lin A. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. Mol. Cell. Biol. 24 (2004) 10844-10856
22. Sabapathy K., Hochedlinger K., Nam S.Y., Bauer A., Karin M., and Wagner E.F. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 15 (2004) 713-725
23. Chang W.C., Chen Y.C., Lee K.M., and Tarn W.Y. Alternative splicing and bioinformatic analysis of human U12-type introns. Nucleic Acids Res. 35 (2007) 1833-1841
24. Bogoyevitch M.A. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting. BioEssays 28 (2006) 923-934
25. Bogoyevitch M.A., and Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol. Mol. Biol. Rev. 70 (2006) 1061-1095
26. Kuan C.Y., Yang D.D., Samanta Roy D.R., Davis R.J., Rakic P., and Flavell R.A. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22 (1999) 667-676
27. Sabapathy K., Jochum W., Hochedlinger K., Chang L., Karin M., and Wagner E.F. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech. Dev. 89 (1999) 115-124
28. Sabapathy K., Kallunki T., David J.P., Graef I., Karin M., and Wagner E.F. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation. J. Exp. Med. 193 (2001) 317-328
29. Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G., et al. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8 (1994) 2996-3007
30. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
31. Alcorn J.F., van der Velden J., Brown A.L., McElhinney B., Irvin C.G., and Janssen-Heininger Y.M. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 40 (2009) 422-432
32. Wu J., Zhang X., Nauta H.J., Lin Q., Li J., and Fang L. JNK1 regulates histone acetylation in trigeminal neurons following chemical stimulation. Biochem. Biophys. Res. Commun. 376 (2008) 781-786
33. Wei Y., Pattingre S., Sinha S., Bassik M., and Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol. Cell 30 (2008) 678-688
34. Hu D., Fang W., Han A., Gallagher L., Davis R.J., Xiong B., et al. c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway. Carcinogenesis 29 (2008) 2317-2324
35. Alter J., Rozentzweig D., and Bengal E. Inhibition of myoblast differentiation by tumor necrosis factor alpha is mediated by c-Jun N-terminal kinase 1 and leukemia inhibitory factor. J. Biol. Chem. 283 (2008) 23224-23234
36. Takatori A., Geh E., Chen L., Zhang L., Meller J., and Xia Y. Differential transmission of MEKK1 morphogenetic signals by JNK1 and JNK2. Development 135 (2008) 23-32
37. Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008) 1972-1983 1983 e1-e11
38. Tanaka S., and Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 100 (2009) 1-8
39. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J. Gastroenterol. 44 Suppl. 19 (2009) 136-141
40. Shrivastava A., Manna S.K., Ray R., and Aggarwal B.B. Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J. Virol. 72 (1998) 9722-9728
41. Tarn C., Lee S., Hu Y., Ashendel C., and Andrisani O.M. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J. Biol. Chem. 276 (2001) 34671-34680
42. Guo L., Guo Y., Xiao S., and Shi X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci. 77 (2005) 1869-1878
43. Ching Y.P., Leong V.Y., Lee M.F., Xu H.T., Jin D.Y., and Ng I.O. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 67 (2007) 3601-3608
44. Deakin N.O., and Turner C.E. Paxillin comes of age. J. Cell. Sci. 121 (2008) 2435-2444
45. Maeda S., Kamata H., Luo J.L., Leffert H., and Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
46. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 11 (2007) 119-132
47. Sakurai T., Maeda S., Chang L., and Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10544-10551
48. Llovet J.M., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48 Suppl. 1 (2008) S20-S37
49. Benowitz S. Liver cancer biomarkers struggling to succeed. J. Natl. Cancer Inst. 99 (2007) 590-591
50. Chen X., Cheung S.T., So S., Fan S.T., Barry C., Higgins J., et al. Gene expression patterns in human liver cancers. Mol. Biol. Cell 13 (2002) 1929-1939
51. Lee J.S., Chu I.S., Heo J., Calvisi D.F., Sun Z., Roskams T., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40 (2004) 667-676
52. Lee J.S., Heo J., Libbrecht L., Chu I.S., Kaposi-Novak P., Calvisi D.F., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12 (2006) 410-416
53. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007) 42-52
54. Ye Q.H., Qin L.X., Forgues M., He P., Kim J.W., Peng A.C., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 9 (2003) 416-423
55. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.Y., et al. EpCAM-positive hepatocellular carcinoma cells are tumor initiating cells with stem/progenitor cell features. Gastroenterology 136 (2009) 10.1053/j.gastro.2008.12.004
56. Rubie C., Frick V.O., Wagner M., Rau B., Weber C., Kruse B., et al. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand. J. Immunol. 63 (2006) 468-477
57. Cairo S., Armengol C., De Reynies A., Wei Y., Thomas E., Renard C.A., et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14 (2008) 471-484
58. Woo H.G., Park E.S., Cheon J.H., Kim J.H., Lee J.S., Park B.J., et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res. 14 (2008) 2056-2064
59. Grate L.R. Many accurate small-discriminatory feature subsets exist in microarray transcript data: biomarker discovery. BMC Bioinformatics 6 (2005) 97
60. Matouk I.J., DeGroot N., Mezan S., Ayesh S., Abu-lail R., Hochberg A., et al. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE 2 (2007) e845
61. Ariel I., Miao H.Q., Ji X.R., Schneider T., Roll D., de Groot N., et al. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol. Pathol. 51 (1998) 21-25
62. Lee Y.C., Pan H.W., Peng S.Y., Lai P.L., Kuo W.S., Ou Y.H., et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur. J. Cancer 43 (2007) 736-744
63. Ieta K., Ojima E., Tanaka F., Nakamura Y., Haraguchi N., Mimori K., et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int. J. Cancer 121 (2007) 33-38
64. Liao Y.L., Sun Y.M., Chau G.Y., Chau Y.P., Lai T.C., Wang J.L., et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene 27 42 (2008) 5578-5589
65. Yumoto E., Nakatsukasa H., Hanafusa T., Yumoto Y., Nouso K., Matsumoto E., et al. IGFBP-3 expression in hepatocellular carcinoma involves abnormalities in TGF-beta and/or Rb signaling pathways. Int. J. Oncol. 27 (2005) 1223-1230
66. Cui J.F., Liu Y.K., Zhang L.J., Shen H.L., Song H.Y., Dai Z., et al. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 6 (2006) 5953-5961
67. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359 (2008) 1995-2004
68. Kim J.W., Ye Q., Forgues M., Chen Y., Budhu A., Sime J., et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 39 (2004) 518-527
69. Neo S.Y., Leow C.K., Vega V.B., Long P.M., Islam A.F., Lai P.B., et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 39 (2004) 944-953
70. Ovejero C., Cavard C., Perianin A., Hakvoort T., Vermeulen J., Godard C., et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 40 (2004) 167-176
71. Uchida T., Nagai H., Gotoh K., Kanagawa H., Kouyama H., Kawanishi T., et al. Expression pattern of a newly recognized protein, LECT2, in hepatocellular carcinoma and its premalignant lesion. Pathol. Int. 49 (1999) 147-151
72. Zollner G., Wagner M., Fickert P., Silbert D., Fuchsbichler A., Zatloukal K., et al. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 25 (2005) 367-379
73. Giannelli G., and Antonaci S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J. Clin. Gastroenterol. 40 (2006) 842-846
74. Crowe D.L., Tsang K.J., and Shemirani B. Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia 3 (2001) 27-32
75. Wang I.C., Chen Y.J., Hughes D.E., Ackerson T., Major M.L., Kalinichenko V.V., et al. FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J. Biol. Chem. 283 (2008) 20770-20778
76. McKenna G.J., Chen Y., Smith R.M., Meneghetti A., Ong C., McMaster R., et al. A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas. Am. J. Surg. 183 (2002) 588-594
77. Rangaswami H., and Kundu G.C. Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol. Rep. 18 (2007) 909-915
78. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25 (2006) 3818-3822
79. Yamashita T., Forgues M., Wang W., Kim J.W., Ye Q., Jia H., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68 (2008) 1451-1461
80. Ma S., Lee T.K., Zheng B.J., Chan K.W., and Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27 (2008) 1749-1758
81. Chen F., Li S., and Castranova V. Signature genes for both hepatoblastoma and hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 21 (2009)
82. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.Y., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136 (2009) 1012-1024
83. Matsuzawa A., and Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim. Biophys. Acta 1780 (2008) 1325-1336
84. Zhang Y., and Chen F. Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res. 64 (2004) 1902-1905
85. Chamberlain S.D., Redman A.M., Wilson J.W., Deanda F., Shotwell J.B., Gerding R., et al. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg. Med. Chem. Lett. 19 (2009) 360-364
86. Conze D., Krahl T., Kennedy N., Weiss L., Lumsden J., Hess P., et al. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J. Exp. Med. 195 (2002) 811-823
87. Singh R., Wang Y., Xiang Y., Tanaka K.E., Gaarde W.A., and Czaja M.J. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 49 (2009) 87-96
88. Dai Y., Rahmani M., Dent P., and Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell. Biol. 25 (2005) 5429-5444
89. Pimienta G., and Pascual J. Canonical and alternative MAPK signaling. Cell Cycle 6 (2007) 2628-2632
90. Tan A., Yeh S.H., Liu C.J., Cheung C., and Chen P.J. Viral hepatocarcinogenesis: from infection to cancer. Liver Int. 28 (2008) 175-188
91. Nijhara R., Jana S.S., Goswami S.K., Rana A., Majumdar S.S., Kumar V., et al. Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo. J. Virol. 75 (2001) 10348-10358
92. Murata M., Matsuzaki K., Yoshida K., Sekimoto G., Tahashi Y., Mori S., et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 49 (2009) 1203-1217
93. Matsuzaki K., Murata M., Yoshida K., Sekimoto G., Uemura Y., Sakaida N., et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46 (2007) 48-57
94. Park K.J., Choi S.H., Koh M.S., Kim D.J., Yie S.W., Lee S.Y., et al. Hepatitis C virus core protein potentiates c-Jun N-terminal kinase activation through a signaling complex involving TRADD and TRAF2. Virus Res. 74 (2001) 89-98
95. Park K.J., Choi S.H., Choi D.H., Park J.M., Yie S.W., Lee S.Y., et al. 1Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. J. Biol. Chem. 278 (2003) 30711-30718
96. Dolganiuc A., Oak S., Kodys K., Golenbock D.T., Finberg R.W., Kurt-Jones E., et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127 (2004) 1513-1524
97. Sekimoto G., Matsuzaki K., Yoshida K., Mori S., Murata M., Seki T., et al. Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res. 67 (2007) 5090-5096
98. Engel M.E., McDonnell M.A., Law B.K., and Moses H.L. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J. Biol. Chem. 274 (1999) 37413-37420
99. Mori S., Matsuzaki K., Yoshida K., Furukawa F., Tahashi Y., Yamagata H., et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 23 (2004) 7416-7429
100. Yamagata H., Matsuzaki K., Mori S., Yoshida K., Tahashi Y., Furukawa F., et al. Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res. 65 (2005) 157-165
101. Rhee S.G., Bae Y.S., Lee S.R., and Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci. STKE 2000 (2000) PE1
102. Salmeen A., Andersen J.N., Myers M.P., Meng T.C., Hinks J.A., Tonks N.K., et al. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423 (2003) 769-773
103. van Montfort R.L., Congreve M., Tisi D., Carr R., and Jhoti H. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 423 (2003) 773-777
104. Gu J.M., Lim S.O., Oh S.J., Yoon S.M., Seong J.K., and Jung G. HBx modulates iron regulatory protein 1-mediated iron metabolism via reactive oxygen species. Virus Res. 133 (2008) 167-177
105. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 (2002) 366-375
106. Gong G., Waris G., Tanveer R., and Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9599-9604
107. Morgan M.J., Kim Y.S., and Liu Z.G. TNFalpha and reactive oxygen species in necrotic cell death. Cell Res. 18 (2008) 343-349
108. Brigelius-Flohe R., Banning A., Kny M., and Bol G.F. Redox events in interleukin-1 signaling. Arch. Biochem. Biophys. 423 (2004) 66-73
109. Shen H.M., Ong C.N., and Shi C.Y. Involvement of reactive oxygen species in aflatoxin B1-induced cell injury in cultured rat hepatocytes. Toxicology 99 (1995) 115-123
110. Chen F., Castranova V., Li Z., Karin M., and Shi X. Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res. 63 (2003) 7689-7693
111. Chen Z.J., and Sun L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33 (2009) 275-286
112. Zhao Y., Conze D.B., Hanover J.A., and Ashwell J.D. Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling. J. Biol. Chem. 282 (2007) 7777-7782
113. Lu Z., Xu S., Joazeiro C., Cobb M.H., and Hunter T. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol. Cell 9 (2002) 945-956
114. Witowsky J.A., and Johnson G.L. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways. J. Biol. Chem. 278 (2003) 1403-1406
115. Widmann C., Johnson N.L., Gardner A.M., Smith R.J., and Johnson G.L. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene 15 (1997) 2439-2447
116. Yamashita M., Ying S.X., Zhang G.M., Li C., Cheng S.Y., Deng C.X., et al. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 121 (2005) 101-113
117. Xu Z., Kukekov N.V., and Greene L.A. POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J. 22 (2003) 252-261
118. Obin M., Shang F., Gong X., Handelman G., Blumberg J., and Taylor A. Redox regulation of ubiquitin-conjugating enzymes: mechanistic insights using the thiol-specific oxidant diamide. FASEB J. 12 (1998) 561-569
119. Shang F., and Taylor A. Oxidative stress and recovery from oxidative stress are associated with altered ubiquitin conjugating and proteolytic activities in bovine lens epithelial cells. Biochem. J. 307 Pt 1 (1995) 297-303
120. Kuntzen C., Sonuc N., De Toni E.N., Opelz C., Mucha S.R., Gerbes A.L., et al. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res. 65 (2005) 6780-6788
121. Mucha S.R., Rizzani A., Gerbes A., Camaj P., Thasler W., Bruns C., et al. JNK inhibition sensitizes hepatocellular carcinoma cells but not normal hepatocytes to TNF-related apoptosis inducing ligand. Gut 58 5 (2009) 688-698
122. Aderca I., Moser C.D., Veerasamy M., Bani-Hani A.H., Bonilla-Guerrero R., Ahmed K., et al. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J. Hepatol. 49 (2008) 373-383
123. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13681-13686
124. Manning A.M., and Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat. Rev. Drug Discov. 2 (2003) 554-565
125. Stebbins J.L., De S.K., Machleidt T., Becattini B., Vazquez J., Kuntzen C., et al. Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16809-16813
126. Bogoyevitch M.A., and Arthur P.G. Inhibitors of c-Jun N-terminal kinases: JuNK no more?. Biochim. Biophys. Acta 1784 (2008) 76-93
127. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
128. Heo Y.S., Kim S.K., Seo C.I., Kim Y.K., Sung B.J., Lee H.S., et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 23 (2004) 2185-2195
129. Gomaa A.I., Khan S.A., Toledano M.B., Waked I., and Taylor-Robinson S.D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 14 (2008) 4300-4308
130. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34